iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region
A2A Inhibitor Clinical Trials Financial Research TIGIT

iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region

Funds will be used to progress iTeos’ two highly innovative clinical-stage oncology programs: a best-in class A2A receptor antagonist and an ADCC-enabled anti-TIGIT antibody drug candidate

Gosselies, Belgium and Cambridge, MA – January 30, 2020 – iTeos Therapeutics SA, a privately-held biotechnology company developing innovative cancer immunotherapies, today announced that it has been awarded a total of €15 million in non-dilutive funding to support the clinical development of its two proprietary anti-cancer drug programs, targeting key mechanisms of immunosuppression that are gaining prominence within industry development pipelines. The funding has been approved on behalf of the Walloon Region by Willy Borsus, Minister of Economy and Research.

Funding of €11.5 million has been awarded to progress iTeos’ lead candidate EOS-850, a best-in-class adenosine A2A receptor antagonist, and will be used to support the ongoing phase 1b/2a clinical trial, underway at four sites across Europe, and will soon expand to clinical sites in the United States. A second award of €3.5 million will support the Phase 1 clinical trial of iTeos’ fully-human ADCC-enabled anti-TIGIT antibody (EOS-448), which is expected to start in Belgium in February 2020.

Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented, “We are grateful to the Walloon Region for its continued support of iTeos Therapeutics. This investment is invaluable as we seek to progress our two clinical programs. During the last three years, iTeos has developed a comprehensive portfolio of immuno-oncology drug candidates, and these additional Walloon region funds will help us evaluate the performance of our promising lead programs in the clinic.”

 

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics

info@iteostherapeutics.com

 

Amber Fennell, Catherine Day, Matthew Neal and Sukaina Virji

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

 

Sarah McCabe

Stern Investor Relations, Inc.

+1 212 362 1200

sarah.mccabe@sternir.com

Related news

  • iTeos Therapeutics Closes $125 Million Series B2 Financing
    A2A Inhibitor Clinical Trials Corporate Financial Research TIGIT

    iTeos Therapeutics Closes $125 Million Series B2 Financing

     - Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint - - Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital - - New investors Janus Henderson Investors, RTW Investments and Invus also participated along with previous Series B investors including MPM Capital and HBM Partners - Cambridge, MA and Gosselies, Belgium – April 1, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today the closing of an oversubscribed Series B2 financing, which raised a total of $125 million. The Series B2 financing round was co-led by RA Capital Management and Boxer Capital, and included new investors Janus Henderson Investors, RTW Investments and Invus along with existing investors MPM Capital, HBM Partners, 6 Dimensions Capital, Curative Ventures, Fund+, VIVES Louvain Technology Fund, SRIW, and SFPI. Proceeds from the financing will support the Company's continued growth and advance the clinical development of its two lead product candidates, EOS-850, a best-in-class adenosine A2A receptor antagonist and EOS-448, an ADCC-enabled anti-TIGIT antibody. EOS-850 is currently being evaluated in a Phase 1/2 clinical trial both as a single agent and in combination in several solid tumor indications. The Company plans to initiate dosing for the combination cohorts for this trial in the second quarter of 2020. The Company also recently initiated the Phase 1 portion of a Phase 1/2 clinical study of EOS-448, currently being evaluated in patients with solid tumors and hematological malignancies. Proceeds from this financing will also support the advancement of additional first-in-class preclinical programs targeting the adenosine pathway and Tregs. "We are very pleased to have the strong support of this leading class of investors who share our excitement for the highly innovative oncology therapies we have developed at iTeos,” said Michel Detheux, PhD, President and Chief Executive Officer at iTeos. “We look forward to accelerating and expanding our clinical development efforts to identify the most promising indications and combinations for people suffering with cancer. This financing maximizes our ability to execute our development plans alone or in partnership.” "iTeos’ pipeline of best-in-class agents has the potential to usher in a new wave of immuno-oncology therapeutics and the Company is well-positioned to make a significant, positive impact in the treatment of patients with a wide variety of cancer types,” commented Derek DiRocco, Principal, RA Capital Management. “We are thrilled to collaborate with this experienced group of high-quality investors and partner with the iTeos management team as they continue to innovate and progress these exciting programs through clinical development.” “The iTeos team has done a remarkable job developing a pipeline of differentiated, potentially best-in-class cancer therapies,” said Aaron Davis, Co-Founder and Chief Executive Officer, Boxer Capital of the Tavistock Group.  “We are pleased to be joining them as they continue to execute and implement their vision for transforming the cancer treatment landscape.” Derek DiRocco and Aaron Davis will join the iTeos Board as Non-Executive Directors. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com. About RA Capital Management RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit https://www.racap.com. About Boxer Capital, LLC Boxer Capital, LLC is a private biotechnology investment fund based in San Diego, California that invents and invests in drug development across multiple therapeutic indications.  Founded by the life sciences team at Tavistock Group in 2005, Boxer Capital maintains a concentrated portfolio of public and private companies.  For more information, please visit www.boxercap.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Announces New  Scientific Advisory Board Members
    A2A Inhibitor Clinical Trials Corporate Research TIGIT

    iTeos Therapeutics Announces New Scientific Advisory Board Members

    Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman,  William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer. The full SAB comprises: Gordon Freeman, Ph.D, Researcher at Boston’s Dana-Farber Cancer Institute, who will become Chairman of the SAB William C. Hahn, M.D.,Ph.D, Chief Research Strategy Officer at Boston’s Dana-Farber Cancer Institute Ben Z. Stanger, M.D, Professor in Cancer Research at the University of Pennsylvania’s Perelman School of Medicine Matthew G. Vander Heiden, Ph.D., Associate Director at the Massachusetts Institute of Technology’s (MIT) Koch Institute for   Integrative Cancer Research Benoit Van den Eynde M.D., Ph.D, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB Pierre Coulie, M.D., Ph.D. Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain Scott Chappel, Ph.D. Chief Scientific Officer at iTeos Therapeutics Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: “By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable. “While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours.” Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: “I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos’ pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A2A pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development.” Additional background on all SAB members can be found on the iTeos website. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US) Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
    A2A Inhibitor TIGIT

    iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019

    Gosselies, Belgium and Cambridge, MA – March 29, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it will present data on the efficacy of its innovative and differentiated A2A receptor antagonist, EOS100850, as well as its human antibody directed against TIGIT, EOS884448, in eight posters at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2019, taking place from March 29 - April 3, 2019 in Atlanta, Georgia.  “We continue to be excited by the preclinical data from our two immuno-oncology programs, both of which promise mono- and combination therapy potential with other anti-cancer treaments,” said Michel Detheux, President and Chief Executive Officer of iTeos Therapeutics. “The preclinical data being presented at AACR demonstrate key differentiation of our A2A receptor antagonist, such as unique prolonged effects of high potency within the adenosine-rich tumor microenvironment and anti-tumor activity in several cancer models and with different drug combinations. The data also provide a deeper understanding of the adenosine pathway in solid tumors. Additionally, our research on the TIGIT activation pathway sheds light on promising strategies to restore anti-tumor immunity.”  The details of the poster presentations are as follows: Title: EOS100850, a non-brain penetrant highly selective A2A receptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3261 Title: EOS100850 potently restores adenosine A2A receptor-dependent suppression of T cell function in the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1  Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3278  Title: Extensive characterization of the adenosine pathway in human solid tumors gives a hint on cancer indication selection for the A2A receptor antagonist EOS100850. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al.  Location: Section 25, Poster 4149  Title: EOS100850 inhibits A2A receptor signaling in human whole blood: two pharmacodynamic assays to monitor EOS100850 activity in clinical studies. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al. Location: Section 25, Poster 4154 Title: EOS100850, an A2A receptor antagonist with prolonged pharmacodynamic activity, mediates the generation of specific durable immune responses in a murine breast cancer model  Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Grégory Driessens, et al.  Location: Section 25, Poster 4147  Title: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells. Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Catherine Hoofd, et al. Location: Section 24, Poster 3240 Title: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells  Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET  Authors: Grégory Driessens, et al. Location: Section 24, Poster 3249 Title: TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity Session: Adaptive Immune Cells in the Tumor Microenvironment Date & Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM ET  Authors: Catherine Hoofd, et al. Location: Section 23, Poster 4969 Full poster abstracts are available on the AACR conference website at www.aacr.org.  About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com  Amber Fennell, Mathew Neal, Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com